Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Concert Pharmaceuticals (CNCE) in Focus: Stock Rises 5.6%

Concert Pharmaceuticals, Inc. CNCE was a big mover last session, as the company saw its shares rise almost 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company, as the stock is now trading above the volatile price range of $12.77 to $14.22 in the past one-month time frame.

In the past 30 days, the company has not seen any estimate revision and the Zacks Consensus Estimate also remained unchanged. Friday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Concert Pharmaceuticals currently has a Zacks Rank #5 (Strong Sell) while its Earnings ESP 0.00%.

A better-ranked med-drugs stock is Calithera Biosciences, Inc. CALA with a Zacks Rank #2 (Buy).

Is CNCE going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
CONCERT PHARMA (CNCE): Free Stock Analysis Report
 
CALITHERA BIOSC (CALA): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research